Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
YMAB Y-mAbs Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: YMAB
Price (delayed)
$4.6
Market cap
$208.3M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.64
Enterprise value
$148.6M
Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product
Highlights
The company's debt fell by 49% YoY and by 26% QoQ
YMAB's revenue is up by 4.9% year-on-year
The EPS has contracted by 31% YoY but it has grown by 4.5% from the previous quarter
The net income has contracted by 30% YoY but it has grown by 4.8% from the previous quarter
Y-mAbs Therapeutics's equity has decreased by 10% YoY and by 2.8% from the previous quarter
The gross margin has contracted by 5% YoY
Key stats
What are the main financial stats of YMAB
Market
Valuations
Earnings
Shares outstanding
45.28M
Market cap
$208.3M
Enterprise value
$148.6M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.33
Price to sales (P/S)
2.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.68
Revenue
$88.66M
Gross profit
$72.55M
Operating income
-$30.84M
Net income
-$28.23M
EBIT
-$30.84M
EBITDA
-$30.39M
Free cash flow
-$19.28M
Per share
Balance sheet
Liquidity
EPS
-$0.64
EPS diluted
-$0.64
Free cash flow per share
-$0.43
Book value per share
$1.98
Revenue per share
$1.97
TBVPS
$2.45
Total assets
$112.61M
Total liabilities
$23.16M
Debt
$603,000
Equity
$89.46M
Working capital
$71.49M
Debt to equity
0.01
Current ratio
4.77
Quick ratio
4.12
Net debt/EBITDA
1.96
Margins
Efficiency
Dividend
EBITDA margin
-34.3%
Gross margin
81.8%
Net margin
-31.8%
Operating margin
-34.8%
Return on assets
-22.7%
Return on equity
-30.6%
Return on invested capital
-115.2%
Return on capital employed
-32.9%
Return on sales
-34.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
YMAB stock price
How has the Y-mAbs Therapeutics stock price performed over time
Intraday
-3.16%
1 week
6.48%
1 month
8.24%
1 year
-61.7%
YTD
-41.25%
QTD
3.84%
Financial performance
How have Y-mAbs Therapeutics's revenue and profit performed over time
Revenue
$88.66M
Gross profit
$72.55M
Operating income
-$30.84M
Net income
-$28.23M
Gross margin
81.8%
Net margin
-31.8%
The net income has contracted by 30% YoY but it has grown by 4.8% from the previous quarter
The company's net margin fell by 24% YoY but it rose by 6% QoQ
YMAB's operating income is down by 23% year-on-year
The operating margin has contracted by 17% YoY but it has grown by 2.2% from the previous quarter
Price vs fundamentals
How does YMAB's price correlate with its fundamentals
Growth
What is Y-mAbs Therapeutics's growth rate over time
Valuation
What is Y-mAbs Therapeutics stock price valuation
P/E
N/A
P/B
2.33
P/S
2.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.68
The EPS has contracted by 31% YoY but it has grown by 4.5% from the previous quarter
YMAB's P/B is 60% below its 5-year quarterly average of 5.8 and 48% below its last 4 quarters average of 4.5
Y-mAbs Therapeutics's equity has decreased by 10% YoY and by 2.8% from the previous quarter
The stock's price to sales (P/S) is 87% less than its 5-year quarterly average of 17.7 and 51% less than its last 4 quarters average of 4.8
YMAB's revenue is up by 4.9% year-on-year
Efficiency
How efficient is Y-mAbs Therapeutics business performance
Y-mAbs Therapeutics's return on equity has decreased by 43% YoY but it has increased by 2.2% QoQ
Y-mAbs Therapeutics's ROA has decreased by 34% YoY but it has increased by 3% from the previous quarter
The ROS has contracted by 17% YoY but it has grown by 2.2% from the previous quarter
The company's return on invested capital fell by 9% YoY but it rose by 4.1% QoQ
Dividends
What is YMAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for YMAB.
Financial health
How did Y-mAbs Therapeutics financials performed over time
The quick ratio has contracted by 25% YoY but it has grown by 12% from the previous quarter
The current ratio has contracted by 22% YoY but it has grown by 15% from the previous quarter
The company's debt is 99% lower than its equity
The company's debt fell by 49% YoY and by 26% QoQ
Y-mAbs Therapeutics's equity has decreased by 10% YoY and by 2.8% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.